AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
Serbia opens Israeli drone factory as defense ties with Elbit deepen
4
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
5
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
More news

Pharma

18 stories about Pharma
מריוס נכט 1

Check Point Founder Invests in Clinical Stage Company Regenera Pharma

02.01.18|Dror Reich
The company intends to use the funding for a phase 3 clinical trial of its drug for sudden vision loss
מיקי שפירא וינשטוק זקלר ושות' Micki Shapira a partner at Weinstock Zecler _alt Co

The Year’s Seven Key Trends in Israeli Mergers and Acquisitions

29.12.17|Micki Shapira
Even without counting the Mobileye deal, 2017 was another strong year for M&A in Israel
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
עובדי טבע בקריית שמונה מפגינים

Employees Protest Outside Teva’s Israeli Facilities

14.12.17|Omer Kabir, Yoav Stoler and Keren-Or Grinberg
The demonstrations outside the company's facilities held Thursday foreshadow a full-out strike planned by the company’s employees for Sunday
מנכ"ל טבע החדש קור שולץ 2

Teva to Let Go 14,000 Employees Over the Next Two Years

14.12.17|Lilach Baumer
The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors
default image

Israeli Pharma Company Wavelength Appoints New CEO

30.11.17|CTech
Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million
מנכ"ל טבע החדש קור שולץ 2

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
default image

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
default image

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
מפעל חברת טבע הר חוצבים ירושלים

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist
Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts
Previous Articles